Food and Drug Administration Research

General Grant Funding
CFDA 93.103 Active Cooperative Agreements (Discretionary Grants)

Program Funding

Annual program obligations reported to SAM.gov.

Latest annual funding (estimated)
$246.9M FY2023
$170.5M
FY16
$208.9M
FY17*
$173.1M
FY18
$198.5M
FY19
$212.4M
FY20
$218.9M
FY21
$255.9M
FY22*
$246.9M
FY23*
* estimated

Who has received this funding

Organizations awarded under CFDA 93.103 (USAspending.gov).

Program Objective

To assist institutions and organizations, to establish, expand, and improve research, demonstration, education and information dissemination activities; acquired immunodeficiency syndrome (AIDS), biologics, blood and blood products, therapeutics, vaccines and allergenic projects; drug hazards, human and veterinary drugs, clinical trials on drugs and devices for orphan products development; nutrition, sanitation and microbiological hazards; medical devices and diagnostic products, radiation emitting devices and materials; food safety and food additives. These programs are supported directly or indirectly by the following Centers and Offices: Center for Biologics Evaluation and Research (CBER); Center for Drug Evaluation and Research (CDER); Center for Devices and Radiological Health (CDRH); Center for Veterinary Medicine (CVM), Center for Food Safety and Applied Nutrition (CFSAN), National Center for Toxicological Research (NCTR), the Office of Orphan Products Development (OPD), the Center for Tobacco Products (CTP), and Office of Regulatory Affairs (ORA), and the Office of the Commissioner (OC). Small Business Innovation Research (SBIR) Programs: to stimulate technological innovation; to encourage the role of small business to meet Federal research and development needs; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation by minority and disadvantaged persons in technological innovation. Funding support for scientific conferences that are relevant to the FDA scientific mission and public health are also available.

Eligibility

Eligible Applicants

  • U.S. territories
  • State
  • State governments
  • Local governments
  • Public nonprofits
  • Other public organizations
  • Federally recognized tribes
  • U.S. territories (incl. universities)
  • Small businesses
  • Native American organizations
  • Other private organizations
  • Quasi-public nonprofits
  • Private nonprofits
  • For-profit organizations

Applicants should review the individual funding opportunity announcement issued under this CFDA program to see which applicant organizations are eligible to apply.

Beneficiaries

  • 14
  • 15
  • 16
  • 18
  • 4
  • 5
  • 7
  • 8
  • 10
  • 9

Applicants should review the individual funding opportunity announcement issued under this CFDA program to see which applicant organizations are eligible to apply.

How to Apply

Award Procedure

Accepted research and non-research grant applications are subject to an objective review for scientific and technical merit. SBIR applications to be funded are subject to a second level review by a National Advisory Council or Board. All approved applications compete for available funds on the basis of scientific merit and programmatic relevance. Applicants should review the individual funding opportunity announcement issued under this CFDA program to see the specific award procedures that apply.

Decision Timeline

  • Approval: From 120 to 180 days
  • Renewal interval: From 120 to 180 days

Research applications: Approximately 4 to 6 months. SBIR applications: Approximately 6 to 9 months. Conference applications: Approximately 6 to 9 months.

Program details & compliance

Use of Funds

Allowed Uses

Research grants are awarded to eligible institutions in the name of a principal investigator for applications that are responsive to programmatic requirements as stated in the Funding Opportunity Announcement (FOA). Funds are to be used for costs as identified in the FOA and as directly allocable, necessary and reasonable to carry out the proposed research aims and objectives. Small Business Innovation Research (SBIR) Phase I grants are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. SBIR Phase II grants for this program are for the competitive continuation of the research initiated in Phase I, and are likely to result in commercial products or processes. Only Phase I awardees are eligible to apply for Phase II support. Conference grants provide partial support for domestic scientific conferences related to the FDA mission.

Required Documentation

Applicants should review the individual funding opportunity announcement issued under this CFDA program for any required proof of certification which must be submitted prior to or simultaneous with submission of an application.

Reporting & Compliance

Audit Required
Yes

Applicable 2 CFR 200 Subparts

  • Subpart B — General Provisions
  • Subpart C — Pre-Federal Award Requirements
  • Subpart D — Post-Federal Award Requirements
  • Subpart E — Cost Principles
  • Subpart F — Audit Requirements

Contacts

Kimberly M. Pendleton — Chief Grants Management Officer
240-402-7610
4041 Powder Mill Road, Beltsville, MD 20705
Data from SAM.gov Federal Assistance Listings. Source published: 2022-09-07. Spec v1.0. Last synced: 2026-06-02 02:46:08.